Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Trial Profile

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Hepatic veno-occlusive disease
  • Focus Expanded access; Registrational; Therapeutic Use
  • Acronyms Treatment IND
  • Sponsors Gentium; Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 25 Jun 2017 Results (n=137) of post hoc analysis of final data of an expanded access protocol in patients developing VOD/SOS after primary chemotherapy without HSCT, presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results of post hoc analysis assessing the impact of timing of initiation of defibrotide after VOD/SOS diagnosis in patients developing VOD/SOS, presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results of post hoc analysis expanded-access program was used to explore Day +100 survival post-HSCT based on bilirubin-level and defibrotide, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top